Subscribe To

Price Alert Latest News Economic Calendar News

MLTX / What Makes MoonLake Immunotherapeutics (MLTX) a New Buy Stock

MoonLake Immunotherapeutics (MLTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Read More

Demo Live Account See Partner Details

Content Topics

What

Makes

Moonlake

Immunotherapeutics

MLTX

Stock

mltx

Posted: Apr 5 2023, 13:42

Author Name: Zacks Investment Research

MLTX News

By Seeking Alpha
September 27, 2023

MoonLake Immunotherapeutics Is Now Thoroughly De-Risked

MoonLake Immunotherapeutics has seen success in the last 5 months after positive data from a phase 2 trial of sonelokimab in hidradenitis suppurativa.

By The Motley Fool
September 12, 2023

Why Shares of MoonLake Immunotherapeutics Are Rising Tuesday

MoonLake is a clinical-stage biotech that focuses on inflammatory diseases. Its lead therapy, sonelokimab, is being tested against several conditions.

By Seeking Alpha
August 27, 2023

Anchored In Innovation: MoonLake Immunotherapeutics Charts A New Course (Rating Upgrade)

MoonLake Immunotherapeutics' financial health improved with $501.8M cash reserves and robust Q2 2023 research advancements. MLTX focuses on sonelokima

By Reuters
July 14, 2023

Exclusive: MoonLake Immunotherapeutics explores sale-sources

MoonLake Immunotherapeutics , a developer of an antibody-derived treatment for inflammatory skin conditions, is exploring a sale, according to people

By The Motley Fool
June 29, 2023

Why MoonLake Immunotherapeutics Stock Skyrocketed This Week

Earlier this week, MoonLake Immunotherapeutics announced positive mid-stage results for its hidradenitis suppurativa treatment. The therapy could beco

By MarketBeat
June 28, 2023

MoonLake Immunotherapeutics Makes a Moonshot on Trials

Clinical stage biotech MoonLake Immunotherapeutics AG NASDAQ: MLTX shares spiked 70% on positive phase two clinical trial results. The company special

By The Motley Fool
June 27, 2023

Why MoonLake Immunotherapeutics Was Such a Healthy Stock Today

Several analysts dramatically increased their price targets on the biotech. This followed very strong clinical trial results for an investigational tr

By The Motley Fool
June 26, 2023

Why Shares of MoonLake Immunotherapeutics Skyrocketed Monday

MoonLake specializes in treating inflammatory conditions. It presented positive Phase 2 trials regarding its lead therapy, sonelokimab.

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.